Alfred Sandrock
Chief Executive Officer chez VOYAGER THERAPEUTICS, INC.
Fortune : 3 M $ au 29/02/2024
Profil
Actuellement, Alfred W. Sandrock occupe le poste de vice-président exécutif chargé de la recherche et du développement chez Biogen, Inc. et de directeur médical chez Biogen Idec, Inc. (Caroline du Nord) (une filiale de Biogen, Inc.). Il est également membre du conseil d'administration de Disarm Therapeutics, Inc. et président de la Fondation PhRMA, membre de l'Académie américaine de neurologie et professeur à la Harvard Medical School. Alfred W. Sandrock a obtenu un diplôme d'études supérieures de la Harvard Medical School, un doctorat de la Harvard University et un diplôme de premier cycle de la Stanford University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
21/02/2024 | 334 954 ( 0,73% ) | 3 M $ | 29/02/2024 |
Postes actifs de Alfred Sandrock
Sociétés | Poste | Début |
---|---|---|
VOYAGER THERAPEUTICS, INC. | Chief Executive Officer | 22/03/2022 |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Director/Board Member | - |
Atalanta Therapeutics, Inc.
Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor. | Director/Board Member | 10/03/2022 |
Verge Analytics, Inc.
Verge Analytics, Inc. BiotechnologyHealth Technology Verge Analytics, Inc. engages in the provision of biotechnology services. It develops drugs for neurodegenerative diseases using computational genomics. The company was founded by Alice Zhang and Jason Chen in 2015 and is headquartered in San Francisco, CA. | Director/Board Member | 08/02/2022 |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Chairman | - |
Harvard Medical School | Corporate Officer/Principal | - |
American Academy of Neurology
American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Corporate Officer/Principal | - |
Longwood Fund Management LLC
Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Alfred Sandrock
Sociétés | Poste | Fin |
---|---|---|
░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░ ░░░░░ ░░░░ ░░░░░░ ░░░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Formation de Alfred Sandrock
Harvard University | Doctorate Degree |
Stanford University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
NEUROCRINE BIOSCIENCES, INC. | Health Technology |
BIOGEN INC. | Health Technology |
VOYAGER THERAPEUTICS, INC. | Health Technology |
PRAXIS PRECISION MEDICINES, INC. | Health Technology |
Entreprise privées | 9 |
---|---|
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
American Academy of Neurology
American Academy of Neurology Miscellaneous Commercial ServicesCommercial Services American Academy of Neurology operates a professional society which represents neurologists and neuroscientists. The company was founded in 1948 and is headquartered in Minneapolis, MN. | Commercial Services |
Longwood Fund Management LLC
Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Finance |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Commercial Services |
Verge Analytics, Inc.
Verge Analytics, Inc. BiotechnologyHealth Technology Verge Analytics, Inc. engages in the provision of biotechnology services. It develops drugs for neurodegenerative diseases using computational genomics. The company was founded by Alice Zhang and Jason Chen in 2015 and is headquartered in San Francisco, CA. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Atalanta Therapeutics, Inc.
Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor. | Commercial Services |
Transition Bio, Inc.
Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles. | Health Technology |